Planned sale: Gilead (NASDAQ: GILD) CFO trims holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $144.23 per share in an open-market transaction. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this trade, he directly holds 179,191 shares of Gilead common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,000 shares ($432,690)
Net Sell
1 txn
Insider
Dickinson Andrew D
Role
Chief Financial Officer
Sold
3,000 shs ($433K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,000 | $144.23 | $433K |
Holdings After Transaction:
Common Stock — 179,191 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Gilead (GILD) CFO Andrew Dickinson do in this Form 4 filing?
Gilead CFO Andrew Dickinson sold 3,000 shares of common stock at $144.23 per share. The transaction was an open-market sale and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
Was the Gilead (GILD) CFO’s stock sale part of a trading plan?
Yes. The Form 4 states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Such plans pre-schedule trades, indicating the sale’s timing was determined in advance rather than on an ad hoc basis.
Does the Gilead (GILD) Form 4 report any option exercises or derivative trades?
No derivative transactions or option exercises are reported in this Form 4. The filing shows only a single non-derivative open-market sale of 3,000 shares of common stock, with no remaining derivative positions listed in the derivative summary.